# A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

> **NCT06888193** · PHASE1 · RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 20 (estimated)

## Conditions studied

- Moderate to Severe Plaque Psoriasis
- Psoriatic Arthritis
- Axial Spondyloarthritis
- Hidradenitis Suppurativa

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT06888193
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-05
- **Primary completion:** 2027-05-03
- **Final completion:** 2027-05-03
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888193, "A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06888193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*